Business
RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns
Reimbursement in Japan will be similar to that of pricing in the United States VALENCIA, Calif. and MELBOURNE, Australia, Sept. 01, 2022 (GLOBE NEWSWIRE) --
About this update from Avita Medical, Inc.
[{"type":"text","content":"Reimbursement in Japan will be similar to that of pricing in the United States\nVALENCIA, Calif. and MELBOURNE, Australia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that COSMOTEC, an M3 Group Company, received insurance coverage in Japan for the RECELL® System for the treatment of acute burns. “We are very pleased that the Japanese MHLW (Ministry of Health, Labour and Welfare) has granted the RECELL System marketing approval with favorable reimbursement that will be aligned with pricing in the United States,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “We look forward to continuing to work with our partner, COSMOTEC, as they launch and promote RECELL in the Japanese market.” The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. “We will utilize the capabilities of our robust team to support the successful launch of RECELL in Japan,” said Mr. Tatsuro Tsutsumi, CEO of COSMOTEC. “With this product in market, we look forward to contributing to the treatment of burn patients with the goal of returning them to their daily lives as soon as possible.” About M3M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, Japan, South Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 Inc. operates in the US, Asia, and Europe with over 4.5 million physician members globally via its portals including MDLinx.com, m3.com, Doctors.net.uk, medigate.net and medlive.cn. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul. Please visit https://corporate.m3.com/en/ for more information. About COSMOTECCOSMOTEC Co., Ltd., e...